Scarica l'app Stockscreener
1.64
5.13%
0.08
Precedente Chiudi:
$1.56
Aprire:
$1.53
Volume 24 ore:
175.30K
Relative Volume:
0.82
Capitalizzazione di mercato:
$22.81M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-12.30%
1M Prestazione:
+10.44%
6M Prestazione:
-96.54%
1 anno Prestazione:
-93.64%
Intervallo 1D:
$1.53
$1.70
Intervallo di 1 settimana:
$1.43
$1.935
Portata 52W:
$1.38
$53.79
Q 32 Bio Inc Stock (QTTB) Company Profile
Nome
Q 32 Bio Inc
Settore
Industria
Telefono
781-999-0232
Indirizzo
830 WINTER STREET, WALTHAM
Confronta QTTB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
QTTB
Q 32 Bio Inc
|
1.64 | 22.81M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.15 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.61 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
649.67 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
259.39 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.77 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Q 32 Bio Inc Stock (QTTB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-11 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2025-02-11 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-12-11 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-12-11 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-12-11 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2024-12-11 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-12-06 | Iniziato | BMO Capital Markets | Outperform |
| 2024-10-24 | Iniziato | Raymond James | Strong Buy |
| 2024-09-11 | Iniziato | Wells Fargo | Overweight |
| 2024-06-17 | Iniziato | Guggenheim | Buy |
| 2024-05-21 | Iniziato | Leerink Partners | Outperform |
| 2024-04-11 | Iniziato | Oppenheimer | Outperform |
| 2024-04-02 | Iniziato | Piper Sandler | Overweight |
| 2023-07-28 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2022-02-22 | Reiterato | BTIG Research | Neutral |
| 2022-02-22 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-02-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-03-02 | Iniziato | Stifel | Hold |
| 2020-12-14 | Ripresa | H.C. Wainwright | Buy |
| 2020-08-11 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-25 | Ripresa | BofA/Merrill | Buy |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-03-16 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-02-24 | Iniziato | Chardan Capital Markets | Buy |
| 2019-11-01 | Iniziato | Oppenheimer | Perform |
| 2019-09-10 | Iniziato | Robert W. Baird | Outperform |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
Mostra tutto
Q 32 Bio Inc Borsa (QTTB) Ultime notizie
Q32 Bio Stock Turns Retail Trader Heads After FDA Grants Fast Track For Alopecia Drug - MSN
Analysts Provide Insight Into Q32 Bio Inc’s (QTTB) Potential. - Stocksregister
Closing Figures: Q32 Bio Inc (QTTB)’s Positive Finish at 1.60, Up 2.89 - DWinneX
Q32 Bio Stock Turns Retail Trader Heads After FDA Grants Fast Track For Alopecia Drug By Stocktwits - Investing.com India
Fierce Biotech Layoff Tracker 2025: Pliant cuts 45% of workforce; Arvinas lays off a third of staffers - Fierce Biotech
Q32 Bio Inc (NASDAQ: QTTB) Prices Could Soar To Much Higher Levels In Coming Months - Marketing Sentinel
Evaluating QTTB’s financial ratios for a profitable investment - uspostnews.com
Q32 Bio Announces FDA Fast Track Designation Granted To Bempikibart (ADX-914) For The Treatment Of Alopecia Areata - marketscreener.com
Q32 Bio Inc. Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata - marketscreener.com
Layoff Tracker: Ono Cuts 83 Employees in Massachusetts - BioSpace
Scotiabank Has Lowered Expectations for goeasy (TSE:GSY) Stock Price - American Banking and Market News
Analysts Set Q32 Bio Inc. (NASDAQ:QTTB) PT at $24.71 - Defense World
Q32 Bio announces board member resignation By Investing.com - Investing.com Nigeria
Q32 Bio IncMark Iwicki Resigns From Q32 Bio Board Effective Dec 31, 2025 - marketscreener.com
Q32 Bio Board Member Mark Iwicki Resigns - TipRanks
Q32 Bio announces board member resignation - Investing.com
Q32 Bio doses first patient in both parts of SIGNAL-AA trial - TipRanks
Q32 Bio Doses First Patients In Both Part A Open-Label Extension And Part B Of Signal-Aa Phase 2A Trial - marketscreener.com
Breakthrough: Q32 Bio's Alopecia Treatment Maintains Effects 7 Months After Last Dose - Stock Titan
Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata - PR Newswire
Raymond James Financial Inc. Buys New Stake in Q32 Bio Inc. (NASDAQ:QTTB) - Defense World
Q32 Bio Files For Mixed Shelf Of Up To $200 MillionSEC Filing - MarketScreener
Wayfair Inc (NYSE: W) Has Dropped -40.68% Year-To-Date (YTD): Any Trouble Coming? - Marketing Sentinel
QTTB stock touches 52-week low at $1.38 amid market challenges By Investing.com - Investing.com South Africa
All You Need to Know About Q32 Bio (QTTB) Rating Upgrade to Buy - MSN
QTTB stock touches 52-week low at $1.38 amid market challenges - Investing.com India
Arbe Robotics Ltd (NASDAQ: ARBE): How To Buy And When To Buy And Its Performance & Trends - Marketing Sentinel
Wayfair Inc (NYSE:W) Up 0.24% Over The Past 30 Days: Any Troubles Ahead? - Marketing Sentinel
Q32 Bio Inc. (NASDAQ:QTTB) Receives $24.71 Average Target Price from Brokerages - Defense World
Biotech layoff tracker: 21 companies cut 1,000 jobs in Q1 2025 - The Business Journals
QTTB stock touches 52-week low at $1.79 amid market challenges By Investing.com - Investing.com South Africa
QTTB stock touches 52-week low at $1.79 amid market challenges - Investing.com India
Immunosuppressive and Anti-complement Therapies in C3 Glomerulopathy - Medscape
Immunosuppressive Therapies in C3 Glomerulopathy - Medscape
Oppenheimer maintains Q32 Bio at Outperform, $20 target - Investing.com India
Oppenheimer maintains Q32 Bio at Outperform, $20 target By Investing.com - Investing.com UK
Wells Fargo & Company Lowers Q32 Bio (NASDAQ:QTTB) Price Target to $15.00 - Defense World
Q32 Bio price target lowered to $15 from $16 at Wells Fargo - TipRanks
Could Aehr Test Systems (AEHR)’s Current Volatility Hinder Its Future Potential? - Marketing Sentinel
Q32 Bio Inc’s Intellectual Property Challenges: Navigating Risks and Competitive Pressures - TipRanks
Q32 Bio Reports Promising Trial Results and Financials - TipRanks
Q32 Bio: Q4 Earnings Snapshot - Midland Daily News
Q32 Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Q32 Bio Inc. SEC 10-K Report - TradingView
Q32 Bio: Q4 Earnings Snapshot -March 11, 2025 at 07:21 am EDT - MarketScreener
Q 32 Bio Inc Azioni (QTTB) Dati Finanziari
Non sono disponibili dati finanziari per Q 32 Bio Inc (QTTB). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Q 32 Bio Inc Azioni (QTTB) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Violette Shelia M. | Chief Scientific Officer |
Oct 11 '24 |
Option Exercise |
3.12 |
4,574 |
14,271 |
17,874 |
| Violette Shelia M. | Chief Scientific Officer |
Oct 08 '24 |
Option Exercise |
3.12 |
13,300 |
41,496 |
13,300 |
0.47%
2.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):